Endometriosis is a chronic condition driven by inflammation, nerve sensitization, and abnormal tissue growth, often leading to persistent pelvic pain and reduced quality of life. This review explores how cannabidiol (CBD) and tetrahydrocannabinol (THC) may interact with the body’s endocannabinoid system (ECS), a key regulator of pain, immune response, and hormonal balance. Researchers highlight that dysfunction of this system may contribute to endometriosis symptoms, including increased inflammation and heightened pain sensitivity.

The article explains that CBD and THC may help influence several pathways involved in the condition. These cannabinoids appear to modulate inflammation, reduce nerve-related pain signaling, and influence immune responses that contribute to lesion growth and symptom severity. Preclinical and observational evidence suggests cannabinoids may help reduce pelvic pain, improve sleep, and support overall quality of life in some individuals. Additionally, cannabinoids may impact processes such as oxidative stress and cellular signaling that are involved in the progression of endometriosis.

Overall, the review concludes that CBD and THC show promise as multi-target compounds that may address both symptoms and underlying biological mechanisms of endometriosis. However, most current evidence comes from early-stage and observational studies, and the authors emphasize the need for well-controlled clinical trials to determine safety, optimal dosing, and long-term effectiveness.

Source:
Cannabidiol and Δ9-Tetrahydrocannabinol in Endometriosis: A Literature Review on Therapeutic Applications and Mechanisms. National Library of Medicine (NIH):
https://pmc.ncbi.nlm.nih.gov/articles/PMC13055161/